Dr. Ciallella is currently director of research operations at Melior Discovery, Inc., where he manages drug development efforts for Melior, as well as partner companies, using unique in vivo screening systems. Previously, Dr. Ciallella was a senior research scientist at Centocor, Inc., a Johnson & Johnson company, where he was responsible for establishing directives for the delivery and use of biopharmaceuticals in nervous system disorders. Prior to joining Centocor, Dr. Ciallella was a research scientist at Cephalon, Inc., leading the in vivo screening efforts to identify novel kinase inhibitors for the treatment of Alzheimer’s disease. Dr. Ciallella received his Ph.D. from the University of Kentucky Sanders Brown Center on Aging and Department of Microbiology and Immunology. His postdoctoral training was at the University of Pittsburgh, where he studied the biochemical links between traumatic brain injury and Alzheimer’s disease. Dr. Ciallella is a member of several scientific societies and a founding member of the International Brain Barriers Society.